PRT7732
Advanced solid tumors and hematologic malignancies
PreclinicalIND-enabling
Key Facts
Indication
Advanced solid tumors and hematologic malignancies
Phase
Preclinical
Status
IND-enabling
Company
About Prelude Therapeutics
Prelude Therapeutics is dedicated to discovering and developing next-generation cancer treatments by targeting validated biological pathways with novel mechanisms. The company leverages its integrated discovery and development platform to advance a pipeline of small molecule candidates designed to address significant unmet needs in oncology. Its most advanced programs target SMARCA2/BRM and CDK9, with multiple candidates in clinical development. As a public company, Prelude is focused on generating clinical proof-of-concept data to validate its approach and create value for patients and shareholders.
View full company profile